Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01094483 · ClinicalTrials.gov registry record · Phase 1
A Study Assessing Inhibition of Serum Thromboxane B2 Levels With PN400 and Low Dose Aspirin
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01094483 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 40 participants.
The verdict
NCT01094483, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The primary hypothesis of this study is that concomitant multiple-dose administration of PN 400 does not interfere with the platelet inhibitory effects of enteric-coated low-dose aspirin (81 mg), as measured by serum thromboxane B2 inhibition.
Interventions
- DRUG Placebo
- DRUG PN400
- DRUG ASA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2010-03 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01094483
The ClinicalTrials.gov registry entry for NCT01094483 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01094483 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01094483 about?
NCT01094483 is a clinical study titled "A Study Assessing Inhibition of Serum Thromboxane B2 Levels With PN400 and Low Dose Aspirin". The primary hypothesis of this study is that concomitant multiple-dose administration of PN 400 does not interfere with the platelet inhibitory effects of enteric-coated low-dose aspirin (81 mg), as measured by serum thromboxane B2 inhibition.
What is the current status of trial NCT01094483?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2010-03. Estimated completion is 2010-05.
What interventions are being tested in trial NCT01094483?
The interventions under investigation include: Placebo (DRUG), PN400 (DRUG), ASA (DRUG).
Who is sponsoring clinical trial NCT01094483?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.